Literature DB >> 26058814

Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma.

Yinying Lu1,2, Wanping Xu2, Junfang Ji3, Dechun Feng4, Carole Sourbier2, Youfeng Yang2, Jianhui Qu1, Zhen Zeng1, Chunping Wang1, Xiujuan Chang1, Yan Chen1, Alok Mishra2, Max Xu2, Min-Jung Lee5, Sunmin Lee5, Jane Trepel5, W Marston Linehan2, Xinwei Wang3, Yongping Yang1, Len Neckers2.   

Abstract

UNLABELLED: The cell fate determinant Numb is aberrantly expressed in cancer. Numb is alternatively spliced, with one isoform containing a long proline-rich region (PRR(L) ) compared to the other with a short PRR (PRR(S) ). Recently, PRR(L) was reported to enhance proliferation of breast and lung cancer cells. However, the importance of Numb alternative splicing in hepatocellular carcinoma (HCC) remains unexplored. We report here that Numb PRR(L) expression is increased in HCC and associated with early recurrence and reduced overall survival after surgery. In a panel of HCC cell lines, PRR(L) generally promotes and PRR(S) suppresses proliferation, migration, invasion, and colony formation. Knockdown of PRR(S) leads to increased Akt phosphorylation and c-Myc expression, and Akt inhibition or c-Myc silencing dampens the proliferative impact of Numb PRR(S) knockdown. In the cell models explored in this study, alternative splicing of Numb PRR isoforms is coordinately regulated by the splicing factor RNA-binding Fox domain containing 2 (RbFox2) and the kinase serine/arginine protein-specific kinase 2 (SRPK2). Knockdown of the former causes accumulation of PRR(L) , while SRPK2 knockdown causes accumulation of PRR(S) . The subcellular location of SRPK2 is regulated by the molecular chaperone heat shock protein 90, and heat shock protein 90 inhibition or knockdown phenocopies SRPK2 knockdown in promoting accumulation of Numb PRR(S) . Finally, HCC cell lines that predominantly express PRR(L) are differentially sensitive to heat shock protein 90 inhibition.
CONCLUSION: Alternative splicing of Numb may provide a useful prognostic biomarker in HCC and is pharmacologically tractable.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26058814      PMCID: PMC4589429          DOI: 10.1002/hep.27923

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

1.  Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones.

Authors:  Xiang-Yang Zhong; Jian-Hua Ding; Joseph A Adams; Gourisankar Ghosh; Xiang-Dong Fu
Journal:  Genes Dev       Date:  2009-02-15       Impact factor: 11.361

2.  Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer.

Authors:  Christine M Misquitta-Ali; Edith Cheng; Dave O'Hanlon; Ni Liu; C Jane McGlade; Ming Sound Tsao; Benjamin J Blencowe
Journal:  Mol Cell Biol       Date:  2010-11-01       Impact factor: 4.272

3.  Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.

Authors:  Melanie B Thomas; Deborah Jaffe; Michael M Choti; Jacques Belghiti; Steven Curley; Yuman Fong; Gregory Gores; Robert Kerlan; Phillipe Merle; Bert O'Neil; Ronnie Poon; Lawrence Schwartz; Joel Tepper; Francis Yao; Daniel Haller; Margaret Mooney; Alan Venook
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

4.  A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients.

Authors:  Stephanie Roessler; Hu-Liang Jia; Anuradha Budhu; Marshonna Forgues; Qing-Hai Ye; Ju-Seog Lee; Snorri S Thorgeirsson; Zhongtang Sun; Zhao-You Tang; Lun-Xiu Qin; Xin Wei Wang
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

5.  Distinct human NUMB isoforms regulate differentiation vs. proliferation in the neuronal lineage.

Authors:  J M Verdi; A Bashirullah; D E Goldhawk; C J Kubu; M Jamali; S O Meakin; H D Lipshitz
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

Review 6.  Heat shock protein 90: the cancer chaperone.

Authors:  Len Neckers
Journal:  J Biosci       Date:  2007-04       Impact factor: 1.826

Review 7.  Fox-1 family of RNA-binding proteins.

Authors:  Hidehito Kuroyanagi
Journal:  Cell Mol Life Sci       Date:  2009-12       Impact factor: 9.261

8.  Rbfox3-regulated alternative splicing of Numb promotes neuronal differentiation during development.

Authors:  Kee K Kim; Joseph Nam; Yoh-Suke Mukouyama; Sachiyo Kawamoto
Journal:  J Cell Biol       Date:  2013-02-18       Impact factor: 10.539

Review 9.  Aberrant alternative splicing is another hallmark of cancer.

Authors:  Michael Ladomery
Journal:  Int J Cell Biol       Date:  2013-09-11

10.  The RNA-binding protein QKI suppresses cancer-associated aberrant splicing.

Authors:  Feng-Yang Zong; Xing Fu; Wen-Juan Wei; Ya-Ge Luo; Monika Heiner; Li-Juan Cao; Zhaoyuan Fang; Rong Fang; Daru Lu; Hongbin Ji; Jingyi Hui
Journal:  PLoS Genet       Date:  2014-04-10       Impact factor: 5.917

View more
  30 in total

Review 1.  Splicing alterations contributing to cancer hallmarks in the liver: central role of dedifferentiation and genome instability.

Authors:  Maddalen Jimenez; María Arechederra; Matías A Ávila; Carmen Berasain
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-31

2.  Regulation of PTEN degradation and NEDD4-1 E3 ligase activity by Numb.

Authors:  Chen Shao; Zhiguo Li; Nihal Ahmad; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2017-04-24       Impact factor: 4.534

Review 3.  Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development.

Authors:  Len Neckers; Brian Blagg; Timothy Haystead; Jane B Trepel; Luke Whitesell; Didier Picard
Journal:  Cell Stress Chaperones       Date:  2018-02-01       Impact factor: 3.667

4.  Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets.

Authors:  Lu Zhang; Xiaoqiao Liu; Xuegong Zhang; Ronghua Chen
Journal:  Mol Genet Genomics       Date:  2015-12-28       Impact factor: 3.291

5.  An alternative splicing signature model for predicting hepatocellular carcinoma-specific survival.

Authors:  Sheng Dong; Li-Jun Lu
Journal:  J Gastrointest Oncol       Date:  2020-10

6.  Numb exon 9 inclusion regulates Integrinβ5 surface expression and promotes breast cancer metastasis.

Authors:  Yangjing Zhang; Sascha E Dho; Kamal Othman; Craig D Simpson; Jessica Lapierre; Andrew Bondoc; C Jane McGlade
Journal:  Oncogene       Date:  2022-02-18       Impact factor: 8.756

7.  Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.

Authors:  Michael A Moses; Yeong Sang Kim; Genesis M Rivera-Marquez; Nobu Oshima; Matthew J Watson; Kristin E Beebe; Catherine Wells; Sunmin Lee; Abbey D Zuehlke; Hao Shao; William E Bingman; Vineet Kumar; Sanjay V Malhotra; Nancy L Weigel; Jason E Gestwicki; Jane B Trepel; Leonard M Neckers
Journal:  Cancer Res       Date:  2018-05-15       Impact factor: 12.701

8.  SFMetaDB: a comprehensive annotation of mouse RNA splicing factor RNA-Seq datasets.

Authors:  Jin Li; Ching-San Tseng; Antonio Federico; Franjo Ivankovic; Yi-Shuian Huang; Alfredo Ciccodicola; Maurice S Swanson; Peng Yu
Journal:  Database (Oxford)       Date:  2017-01-01       Impact factor: 3.451

9.  RBFOX1 and RBFOX2 are dispensable in iPSCs and iPSC-derived neurons and do not contribute to neural-specific paternal UBE3A silencing.

Authors:  Pin-Fang Chen; Jack S Hsiao; Carissa L Sirois; Stormy J Chamberlain
Journal:  Sci Rep       Date:  2016-05-05       Impact factor: 4.379

10.  Identification of hub genes associated with prognosis, diagnosis, immune infiltration and therapeutic drug in liver cancer by integrated analysis.

Authors:  Xinyi Lei; Miao Zhang; Bingsheng Guan; Qiang Chen; Zhiyong Dong; Cunchuan Wang
Journal:  Hum Genomics       Date:  2021-06-29       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.